| In this program, Dr. Sagar Lonial will discuss therapeutic goals of induction therapy as well as the clinical evidence for various novel agent combinations in newly diagnosed transplant and non-transplant eligible multiple myeloma patients. He also discusses the goals and a number of treatment options, including novel combination therapies, for relapsed or refractory multiple myeloma including tailoring patient therapy according to previous clinical response as well as risk factors including age, renal impairment, and presence of comorbidities. |
